Learn More
BACKGROUND Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. METHODS We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer(More)
OBJECTIVE To evaluate the effects of two bariatric procedures versus intensive medical therapy (IMT) on β-cell function and body composition. RESEARCH DESIGN AND METHODS This was a prospective, randomized, controlled trial of 60 subjects with uncontrolled type 2 diabetes (HbA1c 9.7 ± 1%) and moderate obesity (BMI 36 ± 2 kg/m(2)) randomized to IMT alone,(More)
Glycemic control improves immediately after gastric bypass in patients with type 2 diabetes mellitus (T2DM) (1). The Amer-ican Diabetes Association defines complete remission of diabetes as a return to normal glucose levels (HbA 1c , 6%, fasting glucose ,5.6 mmol/L) without glucose-lowering medication for at least 1 year after bariatric surgery (2). Prior(More)
BACKGROUND Antiproliferative agents used in drug-eluting stents (DES) attenuate atherosclerosis, yet DES implantation has been linked to endothelial dysfunction. The downstream effects of DES on new lesion formation have not been previously directly examined. We sought to compare the development of de novo stenoses and need for treatment in the downstream(More)
  • 1